Sanara MedTech ( (SMTI) ) has released its Q3 earnings. Here is a breakdown of the information Sanara MedTech presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sanara MedTech Inc. is a medical technology company specializing in the development and commercialization of innovative surgical products aimed at improving clinical outcomes and reducing healthcare costs. The company primarily operates in the North American surgical tissue repair market, offering a range of advanced biologic products.
In its third quarter of 2025, Sanara MedTech reported a significant increase in net revenue, showcasing a 22% year-over-year growth. The company also transitioned to profitability with a net income from continuing operations, marking a notable improvement from the previous year’s loss.
Key financial highlights include a net revenue of $26.3 million for the third quarter, driven by a 24% increase in sales of soft tissue repair products. The company’s adjusted EBITDA also saw a substantial rise, reaching $4.9 million. Additionally, Sanara MedTech appointed Seth Yon as the new CEO and initiated a strategic realignment by discontinuing its Tissue Health Plus operations to focus on its core surgical business.
Despite the positive financial performance, the company faced a net loss due to discontinued operations, primarily attributed to a noncash asset impairment charge. However, the overall financial health of the company remains strong, with a focus on expanding its surgical business and improving operational efficiency.
Looking ahead, Sanara MedTech’s management remains optimistic about sustaining revenue growth and profitability by continuing to execute its commercial strategy and investing in its core surgical business. The company aims to enhance its market presence and drive long-term value creation.